Navigation Links
Epizyme, Inc. Granted Notice of Allowance of Patent for EPZ-5676

CAMBRIDGE, Mass., Sept. 3, 2013 /PRNewswire-USNewswire/ -- Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 13/310,157 "SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS" with claims covering the novel compound EPZ-5676. Epizyme's EPZ-5676 is a small molecule DOT1L inhibitor designed to treat acute leukemias in which the MLL gene is rearranged due to a chromosomal translocation (MLL-r).

About EPZ-5676

Epizyme is developing EPZ-5676, a small molecule inhibitor of DOT1L created with Epizyme's proprietary product platform, for the treatment of acute leukemias in which the MLL gene is rearranged due to a chromosomal translocation (MLL-r). Due to the translocation, DOT1L is recruited to specific locations in the chromosome where it would not normally be present. As a result, DOT1L causes inappropriate methylation at these locations, which results in the increased expression of genes causing leukemia.

In September 2012, Epizyme initiated a Phase 1 clinical trial for EPZ-5676. The company believes EPZ-5676 is the first HMTi to enter human clinical development. As of August 2013, this program is in the dose escalation phase and is expected to initiate an expansion phase in the second half of 2013 that will exclusively enroll MLL-r patients.

Epizyme retains all U.S. rights to EPZ-5676 and has granted Celgene an exclusive license to EPZ-5676 outside of the United States. Epizyme has partnered with Abbott to develop a companion diagnostic to identify MLL-r patients. Additional information about these partnerships may be found here:

About MLL-r

MLL-r is an aggressive subtype of two of the most common forms of acute leukemia, acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL). The disease predominantly occurs in two different age ranges, an adult population and a pediatric population. Although both age ranges share a common genetic driver, the adult disease is frequently a secondary leukemia resulting from prior chemotherapy for a different, unrelated cancer, while the pediatric disease is sporadic in nature. According to research published in the journal Blood in December 2002, the five-year overall survival rate for adult patients with the MLL-r subtype of AML ranges from approximately 5 to 24 percent. The five-year event-free survival rate in pediatric patients with the most common MLL-r subtype of ALL is approximately 27 percent, as identified in research published in the New England Journal of Medicine in 2004. The total annual incidence of MLL-r in all patients (adult and pediatric, AML and ALL) in major pharmaceutical markets is approximately 4,900 patients, according to a report by Clarion Healthcare commissioned by Epizyme. Patients with MLL-r are routinely diagnosed today with existing tests that are commonly used in clinical settings, and there is high awareness of MLL-r among oncologists.

About Epizyme, Inc.

Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients for a personalized approach to cancer treatment.

SOURCE Epizyme, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Epizyme, Inc. to Present at Upcoming Conferences in September
2. Epizyme, Inc. to Present at Wedbush Securities Life Sciences Management Access Conference in August
3. Epizyme, Inc. to Webcast Conference Call Discussing Second Quarter 2013 Financial Results on July 31, 2013
4. Epizyme, Inc. Announces Pricing of Initial Public Offering
5. Epizyme, Inc. Files Registration Statement for Proposed Initial Public Offering
6. Oncos Therapeutics Granted Orphan Drug Designation for CGTG-102 in Soft Tissue Sarcoma (STS) by FDA and EMA
7. Trevena Granted Key Composition of Matter Patent for TRV027 in U.S.
8. CorMedix Granted Extension of NYSE MKT Listing
9. QRxPharma Granted US Patent On Hybrid Opioids
10. Mapi Pharma Granted United States Patent Covering Glatiramer Depot for Multiple Sclerosis
11. Omeros Ophthalmology Product OMS302 Granted Eligibility for European Centralized Review
Post Your Comments:
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 Research ... of the "Advanced Wound Care Market by Type ... Ulcers), End User (In-Patient Facility, Out-Patient Facility), and Geography ... offering. --> --> ... the description, definition and forecast of the global advanced ...
(Date:11/26/2015)... -- Research and Markets ( ) has ... Horizons and Growth Strategies in the Italian Therapeutic ... Forecasts, Competitive Intelligence, Emerging Opportunities" report to ... --> This new 247-page report provides ... monitoring market, including emerging tests, technologies, instrumentation, sales ...
(Date:11/25/2015)... SYDNEY , Nov. 26, 2015  The total global ... nearly 7% over 2015-2016. Latin America ... Asia , (excluding Japan ), is ... continues to face increased healthcare expenditure. In 2013-2014, ... expenditure declined from 43.5% in 2008-2009 to 41.2% in 2013-2014. ...
Breaking Medicine Technology:
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... Inevitably when ... Many customers choose to buy during the Black Friday and Cyber Monday ... don’t need to search the Internet high and low to find the best massage ...
(Date:11/26/2015)... NE (PRWEB) , ... November 26, 2015 , ... Jobs ... searched by healthcare professionals and offered by healthcare staffing agency Aureus Medical Group ... during the month of October 2015 among those searching for healthcare jobs through the ...
(Date:11/26/2015)... ... November 26, 2015 , ... Health-E-minds ... collaborated with Women’s Web – an online resource for Indian women looking ... and emotional well-being relationship, life balance, stress, professional development, and lifestyle. Health-E-minds ...
(Date:11/25/2015)... ... November 25, 2015 , ... The holiday season ... and pleasing the palates of attendees is of the utmost importance. Whether you ... seasonal get-together, give these recipes a try this holiday season. , Turkey Croquettes ...
(Date:11/25/2015)... ... , ... Dr. John Pierce, Medical Director at the Ageless Forever clinic in ... Capillus272™ Pro laser therapy cap. FDA cleared for safety and efficacy, the Capillus272 offers ... for surgery, prescription pills, or topical foams. , “Capillus272™ Pro is a home-use ...
Breaking Medicine News(10 mins):